PMID- 37306710
OWN - NLM
STAT- MEDLINE
DCOM- 20230717
LR  - 20230718
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 102
IP  - 8
DP  - 2023 Aug
TI  - PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large 
      B-cell lymphoma.
PG  - 2189-2198
LID - 10.1007/s00277-023-05292-5 [doi]
AB  - The prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) 
      is poor. The efficacy of salvage therapy with ICE (ifosfamide, carboplatin, and 
      etoposide) is limited. DLBCL can evade immune surveillance by upregulating 
      programmed cell death ligand 1 (PD-L1). The purpose of this study was to explore 
      the efficacy and safety of programmed cell death 1 (PD-1) blockade combined with 
      ICE regimen (P-ICE) in the treatment of R/R DLBCL patients. In this study, we 
      retrospectively explored efficacy and toxicity in R/R DLBCL patients treated with 
      P-ICE. Prognostic biomarkers, including clinical features and molecular markers 
      related to efficacy, were explored. From February 2019 to May 2020, a total of 67 
      patients treated with the P-ICE regimen were analyzed. The median follow-up time 
      was 24.7 months (range: 1.4-39.6 months), with an objective response rate (ORR) 
      of 62.7% and a complete response rate (CRR) of 43.3%. The 2-year progression-free 
      survival (PFS) and overall survival (OS) rates were 41.1% (95% CI: 35.0-47.2%) 
      and 65.6% (95% CI: 59.5-71.7%), respectively. Age, Ann Arbor stage, international 
      prognostic index (IPI) score, and response to first-line chemotherapy were 
      correlated with the ORR. Grade 3 and 4 adverse events (AEs) related to the P-ICE 
      regimen were reported in 21.5% of patients. The most common AE was 
      thrombocytopenia (9.0%). No treatment-related deaths occurred. In patients with 
      R/R DLBCL, the P-ICE regimen has promising efficacy and mild toxicity.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Ping, Liqin
AU  - Ping L
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China.
FAU - Gao, Yan
AU  - Gao Y
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China.
FAU - He, Yanxia
AU  - He Y
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China.
FAU - Bai, Bing
AU  - Bai B
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China.
FAU - Huang, Cheng
AU  - Huang C
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China.
FAU - Shi, Lina
AU  - Shi L
AD  - Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
FAU - Wang, Xiaoxiao
AU  - Wang X
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China. 
      wangxx@sysucc.org.cn.
FAU - Huang, Huiqiang
AU  - Huang H
AUID- ORCID: 0000-0002-4623-0536
AD  - Department of Medical Oncology, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University 
      Cancer Center, Guangzhou, Guangdong, People's Republic of China. 
      huanghqsysucc@163.com.
LA  - eng
GR  - 2017ZX09304021/National Science & Technology Major Project/
PT  - Journal Article
DEP - 20230612
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - UM20QQM95Y (Ifosfamide)
RN  - BG3F62OND5 (Carboplatin)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Humans
MH  - Ifosfamide
MH  - Carboplatin
MH  - Programmed Cell Death 1 Receptor
MH  - Retrospective Studies
MH  - Etoposide
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - Rituximab
OTO - NOTNLM
OT  - Diffuse large B-cell lymphoma
OT  - Immunotherapy
OT  - PD-1 blockade
OT  - Relapsed/refractory
EDAT- 2023/06/12 13:06
MHDA- 2023/07/17 06:42
CRDT- 2023/06/12 11:03
PHST- 2023/01/03 00:00 [received]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/07/17 06:42 [medline]
PHST- 2023/06/12 13:06 [pubmed]
PHST- 2023/06/12 11:03 [entrez]
AID - 10.1007/s00277-023-05292-5 [pii]
AID - 10.1007/s00277-023-05292-5 [doi]
PST - ppublish
SO  - Ann Hematol. 2023 Aug;102(8):2189-2198. doi: 10.1007/s00277-023-05292-5. Epub 
      2023 Jun 12.